Industry News

Emergent BioSolutions, Inc.. Investors who purchased or otherwise acquired shares between January 11, 2016 and June 21, 2016 inclusive, are encouraged to contact the Firm prior to the September 19, 2016 lead plaintiff motion deadline.. If you purchased shares of Emergent during the Class Period, please contact Joon M. Khang, Esquire, of Khang& Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine,..."/>
IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit against Emergent BioSolutions, Inc. and Reminds Investors with Losses to Contact the Firm
Synta Pharmaceuticals Corp., effective as of July 22, 2016.. The combined company has more than $40 million in cash to advance its research and development..."/>
Madrigal Pharmaceuticals Completes Merger with Synta to Create Leading Cardiovascular-Metabolic Diseases and NASH Company
Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, announced today that it will host a conference call and live audio webcast on Thursday, August 4, 2016, at 8:30 AM ET to report second quarter 2016 financial results and provide a corporate update. The live webcast can be accessed under "Events and Presentations" in the Investor..."/>
Paratek Pharmaceuticals to Report Second Quarter 2016 Financial Results on August 4, 2016
WellCare Names Ryan Randall COO, Georgia
Centene Corporation reported on Thursday that its wholly-owned subsidiary, Health Net Federal Services LLC expects to receive the Department of Defense's TRICARE West Region Contract. Health Net Federal Services is currently the managed care contractor for the TRICARE North Region. With healthcare delivery sometime mid-year of 2017, the TRICARE West Region contract includes a base period with additional five one-year option periods."/>
Centene announces TRICARE West Region Contract award to Health Net Federal Services
Universal Health Services on Thursday declared a dividend of USD0.10 per share of the company's stock. This cash dividend is payable on 15 September 2016 to shareholders of record as of 1 September 2016.. Universal Health Services operates through its subsidiaries, behavioral health facilities, acute care hospitals and ambulatory centers throughout the US, Puerto Rico, the United Kingdom and the US Virgin Islands."/>
Universal Health Services' board authorises USD0.10 per share dividend pay order
Healthways, the largest independent global provider of well-being improvement solutions, and the chairman and founder of Health eVillages, a non-profit that provides..."/>
Healthways CEO and Health eVillages Founder Donato J. Tramuto Appointed to Robert F. Kennedy Human Rights Board of Directors
Teva Pharmaceutical Industries said on Friday that it has priced an additional CHF1.0bn debt offering via its its special purpose finance subsidiary Teva Pharmaceutical Finance Netherlands IV BV. This debt offering consist of the company's CHF300m of 0.125% fixed rate senior notes maturing in 2018; CHF350m of 0.500% fixed rate senior notes maturing in 2022; and CHF350m of 1.000% fixed rate senior notes maturing in 2025.. These notes will be sold at a..."/>
Teva Announces prices CHF1.0bn senior notes in connection with planned acquisition of Actavis Generics
Spark Therapeutics and Pfizer reported on Thursday that it has received US Food and Drug Administration breakthrough therapy designation for SPK-9001 for the treatment of hemophilia B. SPK-9001 is the lead investigational candidate in the companies' SPK-FIX programme in development for the treatment of hemophilia B, added the partnership. The companies entered into a collaboration for the SPK-FIX programme, including SPK-9001, under which, Spark..."/>
Spark Therapeutics and Pfizer partnership awarded US FDA's breakthrough therapy designation for SPK-9001 for hemophilia
Patterson Companies, Inc. today announced that Todd Marshall will join the organization as chief marketing and digital officer. As a member of the company’ s executive team, Marshall will play a role in shaping corporate strategy and will be responsible for overseeing the company’ s marketing strategy, business intelligence and customer experience, including its..."/>
Todd Marshall Joins Patterson Companies as Chief Marketing and Digital Officer
ContraFect Corporation, a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced the pricing of its underwritten public offering of 14,000,000 shares of its common stock and related warrants to purchase 14,000,000 shares of common stock with an exercise price of $3.00 per share at a combined public offering price of $2.50 per..."/>
ContraFect Corporation Prices $35 Million Public Offering of Common Stock and Warrants
Imprimis Pharmaceuticals, Inc., a pharmaceutical company dedicated to making drugs affordable again through its Branded Compounding™ business model, today announced that positive results of a clinical study comparing the efficacy of its injected triamcinolone acetonide, moxifloxacin hydrochloride and vancomycin Dropless Therapy ® formulation to drops commonly prescribed after cataract surgery now appear in the July issue of the..."/>
Peer-Reviewed Study of Dropless Cataract Surgery Shows 'Measurable Benefits' Compared to Drops
Acadia Healthcare Company, Inc. today announced that it will release its 2016 second quarter earnings on Friday, July 29, 2016, before the market opens. Acadia will conduct a conference call with institutional investors and analysts at 11:00 a.m. ET on Friday, July 29, 2016."/>
Acadia Healthcare Announces Date for Second Quarter 2016 Earnings Release
Impax Laboratories reported on Thursday the appointment of Douglas S. Boothe as president of its generics division. Effective 1 August 2016, Boothe will oversee all aspects of the company's generic business, join its executive committee and report directly to the CEO Fred Wilkinson. Most recently, Boothe has served as executive vice president and general manager at Perrigo Company Plc, wth responsibility for US Pharmaceuticals, including Generics..."/>
Impax elects Douglas S. Boothe as president of generics division
Amgen and UCB on Thursday announced the joint submission of a Biologics License Application to the US Food and Drug Administration for romosozumab for the treatment of osteoporosis in postmenopausal women at increased risk of fracture. According to the companies, Romosozumab, an investigational monoclonal antibody, works by binding and inhibiting sclerostin, a protein naturally occurring in the bone, thereby increasing bone formation and..."/>
Amgen & UCB submits Romosozumab's BLA to the US FDA for the treatment of osteoporosis in postmenopausal women
Zynex, an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurodiagnostic equipment, cardiac and blood volume monitoring, announces today the amount of orders received in June for its electrotherapy product line. CEO, Thomas Sandgaard, said: "We processed 2,072 prescription orders for electrotherapy devices in June, a 123%..."/>
Zynex Announces June Orders
FairFX Group fell back despite a positive trading update yesterday. Holidaymakers were queuing around the block for their currency in the lead-up to the EU referendum and they were vindicated when the pound fell the next day."/>
Daily Mail, London, market report column [Daily Mail, London]
Progenics Pharmaceuticals, Inc.,, an oncology company developing innovative medicines and other products for targeting and treating cancer, announced today that it will host a conference call and webcast to review the second quarter ended June 30, 2016 financial results on Thursday, August 4, 2016, at 8:30 a.m. ET.. To participate, please dial 250-8889 or 545-0001 and reference conference ID 53729266. A live webcast will be available in the Media..."/>
Progenics Pharmaceuticals Sets Second Quarter 2016 Financial Results Call for August 4
China Biologic Products, Inc., a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release second quarter 2016 financial results on Thursday, August 4, 2016 after the market closes. The Company's management will hold a conference call at 7:30 a.m. ET on Friday, August 5, 2016, which is 7:30 p.m., Beijing Time on August 5, 2016, to discuss second quarter 2016 results."/>
China Biologic Products to Report Second Quarter 2016 Financial Results
Sequenom, Inc., a life sciences company committed to enabling healthier lives through the development of innovative products and services, today announced it will report financial results for the second quarter 2016 after closing of the NASDAQ Global Market on Wednesday, August 3, 2016.. A conference call hosted by Dr. Dirk van den Boom, President and CEO, and other members of senior management will take place on Wednesday, August 3, at 5:00 p.m...."/>
Sequenom Schedules Second Quarter Results Conference Call for August 3, 2016

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Financials604 Articles
Consumer Discretionary550 Articles
Information Technology542 Articles
Industrials415 Articles
Health Care363 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.